GLP-1 Drug Recalls and Safety Alerts: How to Stay Informed
With millions of people using GLP-1 medications and a growing compounding market, staying informed about recalls, safety alerts, and counterfeit warnings is essential for your safety.
GLP-1 medications like semaglutide and tirzepatide are among the most prescribed drugs in the world. With that scale comes an increased importance of drug safety vigilance. From manufacturing defects to counterfeit products to compounding pharmacy issues, patients need reliable ways to stay informed. This guide covers every type of safety concern you should be aware of and exactly how to monitor for problems.
Current Alert Status
This article provides general guidance on monitoring GLP-1 safety alerts. For the most current recall and safety information, always check FDA.gov directly. If you believe you have experienced a serious adverse event, contact your healthcare provider immediately and report to FDA MedWatch.
Types of Safety Alerts for GLP-1 Medications
Not all safety alerts are equal. Understanding the different categories helps you assess the seriousness of any alert and determine what action to take.
FDA Drug Recalls
A drug recall occurs when a product is removed from the market or a correction is made because it violates FDA regulations or may present a risk. Recalls are classified by severity:
- Class I: The most serious. Reasonable probability that use of the product will cause serious adverse health consequences or death. Rare for GLP-1 medications.
- Class II: Use of the product may cause temporary or medically reversible adverse health consequences, or the probability of serious consequences is remote. Most GLP-1 recalls fall here.
- Class III: Use of the product is not likely to cause adverse health consequences. Typically involves labeling or packaging issues.
FDA Safety Communications
The FDA issues safety communications when new safety information emerges about an approved drug. These are not recalls but alerts to healthcare providers and patients about potential risks, label changes, or new findings from post-market surveillance.
FDA Warning Letters
FDA warning letters are issued to companies or pharmacies that violate FDA regulations. For GLP-1 medications, these often target compounding pharmacies producing substandard products, companies making false marketing claims, or facilities with manufacturing quality issues.
MedWatch Alerts
MedWatch is the FDA's safety information and adverse event reporting program. It serves as both a reporting mechanism and an alert system for new safety information about drugs, biologics, and medical devices.
Notable Safety Events in GLP-1 History
Brand-Name Product Recalls
Brand-name GLP-1 manufacturers have maintained relatively strong safety records, but there have been several notable events:
- Ozempic pen device issues: Novo Nordisk has issued limited voluntary recalls of specific Ozempic pen lots due to potential defects in the injection mechanism, such as needle clogging or difficulty dispensing the correct dose. These affected specific lot numbers and were typically Class II recalls.
- Wegovy supply interruptions: While not a recall, the extended supply shortages of Wegovy raised safety concerns as patients were forced to interrupt treatment, adjust doses without medical guidance, or seek alternative sources of varying quality.
- Label updates: The FDA has required label updates for both semaglutide and tirzepatide products to include additional safety information about potential risks including intestinal obstruction and aspiration during anesthesia due to delayed gastric emptying.
Compounded Product Concerns
The compounded GLP-1 market has seen more safety issues than the brand-name market:
- Potency variations: FDA testing of compounded semaglutide products has found significant variations in actual drug content compared to labeled amounts — some products contained too little active ingredient, others too much
- Sterility failures: Some compounding pharmacies have been found to have sterility issues in their compounding processes, particularly concerning for injectable products
- Unapproved salt forms: The FDA has raised concerns about compounding pharmacies using semaglutide sodium (a salt form) rather than the semaglutide base used in FDA-approved products, arguing these are not the same drug
- Unlicensed operations: Some entities selling "compounded semaglutide" have been found to be operating without proper pharmacy licenses
Counterfeit Product Warnings
The FDA has issued multiple warnings about counterfeit GLP-1 products:
- Counterfeit Ozempic pens: Fake Ozempic injection pens have been found in the U.S. supply chain, particularly through unauthorized distributors. These products may contain incorrect doses, wrong ingredients, or no active ingredient at all.
- Online fraud: Numerous websites have been identified selling fake or unapproved semaglutide products, often at prices that seem too good to be true
- International purchases: Products purchased from overseas pharmacies may not meet FDA quality standards and could be counterfeit
How to Stay Informed
Set Up These Safety Alert Systems
1. FDA Recall Email Alerts
Subscribe to FDA recall notifications at FDA.gov. You can filter by product type to receive only drug-related alerts.
2. FDA MedWatch
Sign up for MedWatch safety alerts at FDA.gov/MedWatch. These cover new safety information, label changes, and drug safety communications.
3. Manufacturer Notifications
Register your Ozempic or Mounjaro pen on the manufacturer's website to receive direct notifications about product issues.
4. Pharmacy Alerts
Ensure your pharmacy has your current contact information so they can notify you of any recalls affecting products you've received.
5. Your Healthcare Provider
Maintain regular check-ins with your prescribing provider. They receive professional safety alerts and can advise you on any concerns.
How to Verify Your Medication
Whether you are using brand-name or compounded GLP-1 medications, you should know how to verify what you are receiving:
For Brand-Name Products (Ozempic, Wegovy, Mounjaro, Zepbound)
- Check the lot number: Located on the pen or packaging. Cross-reference with any active recalls on FDA.gov
- Verify packaging: Look for proper labeling, correct spelling, and manufacturer details. Counterfeit products often have subtle differences in packaging
- Check the NDC number: The National Drug Code should match the official product code listed in the FDA's drug database
- Inspect the medication: The solution should be clear and colorless. Do not use if cloudy, discolored, or contains particles
- Source matters: Only obtain medications from licensed U.S. pharmacies. Be cautious of online pharmacies — verify licensing through your state board of pharmacy or LegitScript
For Compounded Products
- Request a Certificate of Analysis (COA): This document verifies potency, sterility, and purity testing results for your specific batch
- Verify pharmacy licensure: Check your compounding pharmacy's credentials through your state board or FDA's outsourcing facility registry
- Check for lot numbers and beyond-use dates: Properly compounded products should always include this information on the label
- Verify proper storage: Products should arrive with cold-chain packaging if temperature-sensitive
How to Report Problems
If you experience an adverse event or suspect a quality problem with your GLP-1 medication, reporting it helps protect other patients and contributes to drug safety oversight.
Report Adverse Events
- FDA MedWatch: FDA.gov/MedWatch
- Phone: 1-800-FDA-1088
- Your Provider: Report to your prescribing provider
- Manufacturer: Contact Novo Nordisk or Eli Lilly directly
Report Product Quality Issues
- FDA: Use MedWatch for quality concerns
- State Board: Report compounding issues to your state pharmacy board
- Pharmacy: Notify your dispensing pharmacy
- Counterfeits: Report to FDA's Office of Criminal Investigations
Practical Steps to Protect Yourself
- Use licensed pharmacies only: Never purchase GLP-1 medications from social media, unverified websites, or individuals
- Keep records: Save lot numbers, pharmacy receipts, and any COAs for your compounded medications
- Inspect each delivery: Check packaging integrity, temperature indicators, and medication appearance
- Do not share medications: Never use someone else's prescription medication
- Store properly: Follow storage instructions on the label — most GLP-1 pens require refrigeration before first use
- Stay connected: Maintain regular appointments with your healthcare provider
For more information about GLP-1 treatments and safe access, visit our treatments page or learn how GLP-1 medications work.
Medical Disclaimer
This article is for informational and educational purposes only. It does not constitute medical or legal advice. For the most current recall and safety information, visit FDA.gov. If you experience a medical emergency, call 911 or go to your nearest emergency room. Always consult your healthcare provider about medication safety concerns.
Safe, Verified GLP-1 Access
Trimi Health works exclusively with verified, licensed pharmacies to ensure medication quality and safety.
Get Started TodayMore on FDA and legal
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).